| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lineage Cell Therapeutics, Inc.$1.28
-0.01 (-0.78%)
D 29Pipeline Score Overvalued Biotech · Commercial
Market Cap
324.09 M
EPS
-0.28
P/E Ratio
-
Value Trade
973.63 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
1.73 M
R&D Expenses
4.23 M
Operating CF
-8.08 M
Total Assets
109.53 M
Total Liabilities
56.84 M
Equity
53.88 M
D/E Ratio
12,345
3.17 %
Week
-22.16 %
1 Month
-25.29 %
3 Month
-23.53 %
6 Month
-45.38 %
5 Year
-47.23 %
All Time
Cash Data
Cash Position
53.38 M
Monthly Burn
2.69 M
Runway
17.8 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
738.91 K
52 Week Range
0.64 - 2.09
% held by Insiders
24.81 %
% held by Institutions
25.12 %
Enterprise Value
271.92 M
Total Shares
249.17 M
Short %
14.34 %
Float Shares
196.60 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lineage Cell Therapeutics, Inc.
708Total events
2Upcoming
162Tier-1 (high impact)
2012 – 2027Coverage
Upcoming catalysts 2
Event history 706
Jul 6, 2026
◆Oral PresentationPresentation
Presentation at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
May 12, 2026
▲Full ResultsRG6501Clinical Data
Positive 3-year Phase 1/2a clinical data of RG6501 (OpRegen) presented at Retinal Therapeutics Innovation Summit 2026
geographic atrophysource ↗
May 12, 2026
▲Trial InitiationCOR1Trial
Launched new corneal endothelial disease cell therapy program COR1
corneal endothelial diseasesource ↗
May 12, 2026
▲Manufacturing MilestoneCMC / Inspection
Met first milestone for AlloSCOPE 5D manufacturing initiative (ILT1) at 0.5L scale
Type 1 Diabetessource ↗
May 12, 2026
▲First Patient DosedOPC1Trial
Second chronic SCI patient treated in DOSED study with OPC1
spinal cord injurysource ↗
May 12, 2026
▲Trial InitiationTrial
Established Scientific Advisory Board with Joachim Fruebis as founding member
May 12, 2026
◆Enrollment UpdateRG6501Trial
Phase 2a GAlette study currently enrolling at 17 sites in U.S. and Israel
geographic atrophysource ↗
May 12, 2026
▲Manufacturing MilestoneReSonanceCMC / Inspection
Completed 3 engineering manufacturing runs for ReSonance
hearing losssource ↗
May 12, 2026
▲Preclinical PoCReSonancePreclinical
Established novel model of deafening to support ReSonance functional testing
hearing losssource ↗
May 12, 2026
▲Trial InitiationOPC1Trial
Opened second clinical site (Rancho Research Institute) for DOSED study
spinal cord injurysource ↗
Drug Pipeline Intelligence
D29
Pipeline Score $64M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.2x
rNPV / MCap Top 32%
Micro Cap (rank 621 of 912)
Percentile RankLineage Cell Therapeutics, Inc. faces pipeline headwinds (29/100), with $338M risk-adjusted pipeline value, led by GRNOPC1 in Spinal Cord Injury (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRNOPC1 Monoclonal antibody | Spinal Cord Injury | Phase 1 | NCT01217008 | 13% | $139M | COMPLETED | 5 | - | - | Jul 1, 2013 | - | Jun 18, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RG6501 | — | Phase 1/2a | 2026-05-12 | sustained gains in best corrected visual acuity (BCVA); partial structural restoration of the retina; re-appearance of an RPE layer; features associated with recovery of photoreceptors Read More | LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen ) Featured at Retinal Therapeutics Innovation Summi Read More | |
RG6501 | — | Phase 1/2a | 2026-05-12 | sustained gains in best corrected visual acuity (BCVA); partial structural restoration of the retina; re-appearance of an RPE layer; features associated with recovery of photoreceptors Read More | LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen ) Featured at Retinal Therapeutics Innovation Summi Read More | |
RG6501 | — | Phase 1/2a | 2026-05-12 | sustained gains in best corrected visual acuity (BCVA); partial structural restoration of the retina; re-appearance of an RPE layer; features associated with recovery of photoreceptors Read More | LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen ) Featured at Retinal Therapeutics Innovation Summi Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LCTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LCTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LCTXLineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
Lineage Cell Therapeutics is scheduled to present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit. The event will provide a platform for the company to discuss its advancements and strategies in the biopharmaceutical sector. Further details about the presentation or specific topics were not disclosed in the article.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen ) Featured at Retinal Therapeutics Innovation Summi
Lineage Cell Therapeutics reported positive first quarter 2026 financial results and updates on various clinical programs. Notable achievements include favorable data from the three-year Phase 1/2a study of RG6501 (OpRegen) presented at a major summit, the launch of a new corneal endothelial cell therapy program, and advancements in their spinal cord injury clinical trials. The company also established a Scientific Advisory Board and met key milestones in their manufacturing initiatives, reflecting their ongoing commitment to developing innovative cell therapies.
Read more →LCTX▼ -5.6%on this news
LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive RG6501 (OpRegen Cell Therapy ) Phase 1/2a Clinical Study 36 Month Results Featured at C
Lineage Cell Therapeutics has reported strong financial results for the fourth quarter and full year 2025, highlighting multiple successes in its RG6501 (OpRegen Cell Therapy) program. The Phase 1/2a clinical trial results have shown sustained improvements in visual acuity for treated patients over 36 months. The company has achieved key milestones with Genentech, validating its manufacturing processes and opening new avenues for treatment, including collaborations aimed at addressing sensorineural hearing loss and Type 1 diabetes. The CEO expressed optimism for further advancements in 2026 with a commitment to evolving their institutional capabilities.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ● Positive RG6501 (OpRegen ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit
Lineage Cell Therapeutics reported its third quarter 2025 financial results, highlighting positive 36-month outcomes from the RG6501 (OpRegen) Phase 1/2a study. The company announced a collaboration with William Demant Invest to develop the ReSonance program for hearing loss and revealed plans for a new Type 1 diabetes initiative. Despite the positive developments, the company reported a significant net loss of $29.8 million, along with a decrease in total revenues compared to the previous year. Overall, Lineage continues to focus on advancing its innovative cell therapies while addressing operational challenges.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive RG6501 (OpRegen ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summi
Lineage Cell Therapeutics reported its second quarter 2025 financial results, highlighting significant advancements in its OpRegen and OPC1 programs. Notable outcomes from the 36-month clinical study of OpRegen showed sustained improvements in visual acuity, challenging previously held beliefs about geographic atrophy. The company also celebrated the first successful treatment of a chronic spinal cord injury patient using a novel delivery system and reported enhancements in its cell production capabilities. However, financial results showed increased losses due to rising operating expenses and impairment costs.
Read more →LCTXOPREGEN (RG6501) 36-MONTH VISUAL ACUITY RESULTS FEATURED AT CLINICAL TRIALS AT THE SUMMIT 2025 • Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to the Geographic Atr
Lineage Cell Therapeutics has presented promising 36-month results from their Phase 1/2a study of OpRegen (RG6501) for treating Geographic Atrophy (GA) due to age-related macular degeneration. The data indicate significant vision improvements among patients who received extensive coverage with OpRegen, showing mean gains of +9 letters. Sustained retinal structural improvements were also observed, challenging the notion of irreversible damage from GA. The ongoing GAlette study aims to further explore the treatment delivery methods and efficacy.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • RG6501 (OpRegen ) Phase 1/2a Clinical Study 36 Month Results to be featured June 21 st at Clinical Trials at th
Lineage Cell Therapeutics has reported its first quarter financial results for 2025, highlighting optimistic advancements in its clinical studies, particularly with OpRegen. Notable updates include the upcoming presentation of 36-month results from the RG6501 (OpRegen) Phase 1/2a study at the Clinical Trials at the Summit 2025. The company initiated a new clinical study for the OPC1 delivery device, aiming to address spinal cord injuries. Despite some operational losses, revenues increased slightly, reflecting a growing collaboration with Roche.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Positive 24 Month Visual Acuity Data with OpRegen in Geographic Atrophy Patients Reported at 202
Lineage Cell Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting positive outcomes from its OpRegen program for patients with geographic atrophy. The company received RMAT designation from the FDA, indicating potential for accelerated development. They announced two financings totaling $44 million and partnered with Genentech to support ongoing drug development. Although revenues increased, the company's operational losses demonstrate a continued financial challenge.
Read more →LCTXLineage Cell Therapeutics Announces CLOSING OF SECOND TRANCHE OF PREVIOUSLY ANNOUNCED Registered Direct Offering Lineage Has Now Received $30 Million in Gross Proceeds and May Receive an Additional $36 Million in Gross P
Lineage Cell Therapeutics has successfully closed the second tranche of its registered direct offering, securing an additional $30 million in gross proceeds. The total gross proceeds from both tranches now amount to $66 million, with potential further funding of $36 million dependent on the exercise of warrants linked to clinical milestones. Shareholder approval was received for the issuance of new common shares, reflecting positive investor sentiment towards the company's future potential. However, the company acknowledges certain risks related to the execution of these warrants.
Read more →LCTX▼ -29%on this news
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering $30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Miles
Lineage Cell Therapeutics has announced a registered direct offering of up to $66 million, consisting of $30 million upfront and potential additional proceeds of $36 million from common warrant exercises. The company has entered agreements with institutional investors and Broadwood Partners, an affiliate of a board member. The offering is expected to close on or about November 21, 2024, but is subject to various closing conditions, including shareholder approval for a portion of the sale. Proceeds will be used for working capital, general corporate purposes, and R&D expenses.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • OpRegen Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA • ReSonance (ANP1) Pr
Lineage Cell Therapeutics has reported its financial results for Q3 2024, highlighting a strong increase in revenues to $3.8 million, driven by collaboration revenues. The company achieved a significant milestone with the FDA granting RMAT designation for its OpRegen therapy aimed at treating geographic atrophy due to age-related macular degeneration. Additionally, promising preclinical results for ReSonance, a therapy targeting hearing loss, were presented recently. However, Lineage continues to face operational losses, amounting to $3.0 million in the reported quarter.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • 24 Month Visual Acuity Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene
Lineage Cell Therapeutics has reported its second quarter 2024 financial results, highlighting promising visual acuity benefits from its OpRegen therapy. The collaboration with Roche and Genentech continues to expand, with activities underway to enhance the OpRegen program. However, the company faced a revenue decline and an increase in operational losses compared to the prior year. Upcoming clinical trials for the OPC1 program are also in preparation, aiming to address spinal cord injuries, signaling an ongoing commitment to innovation in cell therapies.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ● Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen Program ●
Lineage Cell Therapeutics has reported its first quarter 2024 financial results, highlighting a new services agreement established with Genentech to advance the OpRegen program. The company shared positive clinical data regarding long-term visual benefits from its OpRegen therapy, which was recently presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit. Despite these advancements, the company experienced a decrease in total revenue and an increase in net loss compared to the same period last year. Additionally, the appointment of Dr. Charlotte Hubbert as Vice President of Corporate Development aims to strengthen the company's leadership amidst ongoing operational advancements.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • Advanced OpRegen For Dry AMD in Phase 2a Study in Collaboration with Roche and Genentech •
Lineage Cell Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting a strategic partnership with Roche and Genentech for its OpRegen program in a Phase 2a study for dry AMD. The company successfully closed a $14 million direct offering to strengthen its financial position and initiated the development of a hypoimmune iPSC cell line for neurology indications. Despite reporting a decrease in overall revenue and an operational loss, the firm showcased positive advancements in clinical trials, including the IND clearance for its OPC1 program. Looking ahead, Lineage remains focused on reaching significant milestones throughout 2024.
Read more →LCTX▲ +6.7%on this news
LINEAGE CELL THERAPEUTICS ANNOUNCES $14.0
Lineage Cell Therapeutics, Inc. announced a definitive agreement for a registered direct offering, aiming to raise $14 million by selling approximately 13.5 million common shares at $1.04 each. The offering will primarily support clinical trials, research and development, and general corporate purposes. Notably, board members are participating in the offering, reflecting their confidence in the company's direction. The anticipated closing of this offering is set for around February 8, 2024, pending customary conditions being met.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen ) in Patients with Geographic Atrophy (GA) Secondary
Lineage Cell Therapeutics reported its financial results for Q3 2023, showcasing a continued emphasis on its Phase 2a clinical study of OpRegen for treating geographic atrophy. The company announced a patent grant for its RPE cell manufacturing process and plans to submit an investigational new drug amendment for OPC1 by the end of Q4 2023. However, it also faced a decline in overall revenues and an increase in operational losses compared to the prior year, reflecting both challenges and advancements in its research endeavors.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen ) in Patients with GA Secondary to AMD Under Managem
Lineage Cell Therapeutics reported its second quarter 2023 financial results, highlighting ongoing enrollment in the Phase 2a clinical study of OpRegen, a treatment for geographic atrophy secondary to age-related macular degeneration. The company also reported positive topline results from the Phase 1 VAC2 study for non-small cell lung cancer. Despite these advancements, total revenues decreased compared to the previous year, driven by a decline in collaboration and licensing revenues. Lineage's inclusion in the Russell 3000 Index and the establishment of an investor symposium reflect its growing influence in the field.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Additional RG6501 (OpRegen ) Phase 1/2a Clinical Study Results Presented at ARVO 2023 Enrolling Phase 2a Clinical Study
Lineage Cell Therapeutics reported its financial results for the first quarter of 2023, highlighting a significant cash position of $46.8 million. The company is progressing with its OpRegen therapy, currently in a Phase 2a clinical trial for geographic atrophy secondary to age-related macular degeneration, while also pursuing new collaborations to support its initiatives. However, the company saw a revenue decline to $2.4 million in Q1 2023, driven by reduced collaboration revenues compared to the previous year. Despite this, overall operating expenses decreased, indicating some financial management improvements.
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Phase 2a Clinical Study of RG6501 (OpRegen ) in Patients with GA Secondary to AMD Initiated by Genentech,
Lineage Cell Therapeutics, Inc. has reported its financial results for the fourth quarter and full year 2022, highlighting key achievements and ongoing collaborations. The company initiated a Phase 2a clinical study of its OpRegen product in partnership with Roche and Genentech, alongside launching new therapies targeting hearing and vision loss. Additionally, they established a new R&D facility while expanding existing manufacturing capabilities. Despite reporting increased revenues, Lineage also noted operating losses and decreased revenues from grants and royalties.
Read more →LCTX▲ +6.4%on this news
LINEAGE CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Appointed Jill Howe as Chief Financial Officer Established New R&D Facility and Expanded Existing cGMP Manufacturing Fac
CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Appointed Jill Howe as Chief Financial Officer Established New R&D Facility and Expanded Existing cGMP Manufacturing Facility Received Notice of Allowance for Patent Applications Co
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTs SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Advanced RG6501 (OpRegen ) Development in Partnership with Roche and Genentech Published OPC1 Phase 1/2a Clinical Study
CELL THERAPEUTICS REPORTs SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Advanced RG6501 (OpRegen ) Development in Partnership with Roche and Genentech Published OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: Spine Completed Key Acti
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Reported RG6501 (OpRegen ) Clinical Results at 2022 ARVO Meeting; Outer Retinal Structure Improvement Observed in Five D
CELL THERAPEUTICS REPORTs FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Reported RG6501 (OpRegen ) Clinical Results at 2022 ARVO Meeting; Outer Retinal Structure Improvement Observed in Five Dry AMD Patients Expanded Pipeline with Two New Cell Therapy Dev
Read more →LCTX▲ +7.5%on this news
RG6501 (OPREGEN ) PHASE 1/2A CLINICAL RESULTS SUPPORT THE POTENTIAL FOR OPREGEN TO SLOW, STOP OR REVERSE DISEASE PROGRESSION IN GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION 12-Month Primary Endpoint D
(OPREGEN ) PHASE 1/2A CLINICAL RESULTS SUPPORT THE POTENTIAL FOR OPREGEN TO SLOW, STOP OR REVERSE DISEASE PROGRESSION IN GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION 12-Month Primary Endpoint Data Suggest OpRegen is Well Tolerated with an Acceptable Safety
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Deve
CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Development and Commercialization of RG6501 (OpRegen ) in Transaction
Read more →LCTX▲ +21.2%on this news
LINEAGE ESTABLISHES EXCLUSIVE WORLDWIDE COLLABORATION WITH GENENTECH FOR THE DEVELOPMENT AND COMMERCIALIZATION OF OPREGEN RPE CELL THERAPY FOR THE TREATMENT OF OCULAR DISORDERS Genentech Will Pay Lineage $50 Million Upfr
ESTABLISHES EXCLUSIVE WORLDWIDE COLLABORATION WITH GENENTECH FOR THE DEVELOPMENT AND COMMERCIALIZATION OF OPREGEN CELL THERAPY FOR THE TREATMENT OF OCULAR DISORDERS Genentech Will Pay Lineage $50 Million Upfront Eligible to Receive a Total of $670 Million in Upfront and Mi
Read more →LCTX▲ +13%on this news
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen Four Patients With Dry Age-Related Macular Degeneration Observed to Have Areas of Geographic Atrophy Which Diminished or Remained Unchanged Relative
Reports Fourth Case of Retinal Tissue Restoration With OpRegen CA- November 30, 2021 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that resto
Read more →LCTXLINEAGE REPORTs THIRD QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS OpRegen Continues to Demonstrate Functional and Anatomical Improvements in Patients with Dry AMD Performanc
REPORTs THIRD QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS OpRegen Continues to Demonstrate Functional and Anatomical Improvements in Patients with Dry AMD Performance Testing Underway to Support New Delivery Device for OPC1 Clin
Read more →LCTXPROMISING NEW OpREGEN CLINICAL DATA FEATURED AT 54 TH ANNUAL RETINA SOCIETY MEETING IN PODIUM PRESENTATION BY CHRISTOPHER D. RIEMANN, M.D. Statistically Significant Evidence of a Treatment Effect with OpRegen Observed in
NEW OpREGEN CLINICAL DATA FEATURED AT 54TH ANNUAL RETINA SOCIETY MEETING IN PODIUM PRESENTATION BY CHRISTOPHER D. Significant Evidence of a Treatment Effect with OpRegen Observed in Cohort 4 Patients CA- September 30, 2021 - Lineage Cell Therapeutics, Inc. (NYSE American and T
Read more →LCTXLINEAGE REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS OpRegen Continued to Demonstrate Functional and Anatomical Improvements in Patients with Dry AM
REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS OpRegen Continued to Demonstrate Functional and Anatomical Improvements in Patients with Dry AMD Three Cases of Retinal Tissue Restoration Reported; Longest o
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS ADDITIONAL CASES OF RETINAL TISSUE RESTORATION IN DRY AMD PATIENTS TREATED WITH OPREGEN RPE CELLS Restoration Was Observed in Two Additional Patients in a Phase 1/2a Clinical Study of Op
CELL THERAPEUTICS REPORTS ADDITIONAL CASES OF RETINAL TISSUE RESTORATION IN DRY AMD PATIENTS TREATED WITH OPREGEN RPE Restoration Was Observed in Two Additional Patients in a Phase 1/2a Clinical Study of OpRegen An Earlier and First-Known Clinical Report of Restoration Has B
Read more →LCTXLINEAGE REPORTs FIRST QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS SIGNIFICANT PROGRESS WITH ALL THREE CLINICAL PROGRAMS OpRegen Clinical Data Continued to Demonstrate Improvements in Dry Age-Related Macular Degeneratio
REPORTs FIRST QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS SIGNIFICANT PROGRESS WITH ALL THREE CLINICAL PROGRAMS OpRegen Clinical Data Continued to Demonstrate Improvements in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) Worldwide License Agreement
Read more →LCTXOpREGEN CLINICAL DATA CONTINUES TO DEMONSTRATE IMPROVEMENTS IN PATIENTS WITH DRY AMD WITH GEOGRAPHIC ATROPHY Eighty-Three Percent of All Cohort 4 Patients Exhibited Stable or Improved BCVA Visual Acuity Declined in the M
CLINICAL DATA CONTINUES TO DEMONSTRATE IMPROVEMENTS IN PATIENTS WITH DRY AMD WITH GEOGRAPHIC ATROPHY Eighty-Three Percent of All Cohort 4 Patients Exhibited Stable or Improved BCVA Visual Acuity Declined in the Majority of Untreated Eyes Positive Interim Outcomes on Patie
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Completed Enrollment in Phase 1/2a Clinical Trial of OpRegen for the Treatment of Dry Age-Related Macular
CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Completed Enrollment in Phase 1/2a Clinical Trial of OpRegen for the Treatment of Dry Age-Related Macular Degeneration Announced First Known Report of Human Retinal Tis
Read more →LCTXLINEAGE CELL THERAPEUTICS PRESENTS NEW OPREGEN DATA FOR DRY AMD WITH GA AT 2020 AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING Improved Visual Acuity Continues to be Observed in Cohort 4 Patients First Known Clinical R
CELL THERAPEUTICS PRESENTS NEW OPREGEN DATA FOR DRY AMD WITH GA AT 2020 AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING Improved Visual Acuity Continues to be Observed in Cohort 4 Patients First Known Clinical Report of Retinal Tissue Regeneration Persisted to 23 Months wi
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Reported Encouraging VAC2 Clinical Data in the Ongoing Phase 1 Trial in Non-Small Cell Lung Cancer Enrolled Additional P
CELL THERAPEUTICS REPORTS THIRD QUARTER 2020 RESULTS AND PROVIDES BUSINESS UPDATE Reported Encouraging VAC2 Clinical Data in the Ongoing Phase 1 Trial in Non-Small Cell Lung Cancer Enrolled Additional Patients in Final Cohort of OpRegen Phase 1/2a Clinical Trial for the Tre
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE on ALL clinical programs Announced First Known Reported Finding of Retinal Tissue Restoration Following OpRegen RPE Cell Transpl
CELL THERAPEUTICS REPORTS SECOND QUARTER 2020 RESULTS AND PROVIDES UPDATE on ALL clinical programs Announced First Known Reported Finding of Retinal Tissue Restoration Following OpRegen RPE Cell Transplant Exercised Option with Cancer Research UK for VAC Immuno-Oncology Cel
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Presented Positive New Data from Phase 1/2a Clinical Study of OpRegen in Dry AMD at 2020 ARVO Virtual Meeting Announced
CELL THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Presented Positive New Data from Phase 1/2a Clinical Study of OpRegen in Dry AMD at 2020 ARVO Virtual Meeting Announced Early Exercise of Option with Cancer Research UK for Immuno-Onc
Read more →LCTXLINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Reported Positive Data from Phase 1/2a Clinical Trial of OpRegen ; All Cohort 4 Patients Have Improved Vi
CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Reported Positive Data from Phase 1/2a Clinical Trial of OpRegen ; All Cohort 4 Patients Have Improved Visual Acuity at Twelve Months or as of Last Visit (Gained Between
Read more →LCTXliNEAGE CELL THERAPEUTICS ReportS THIRD Quarter 2019 Financial Results AND PROVIDES BUSINESS UPDATE New Data from Phase I/IIa Clinical Study of OpRegen Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Vis
CELL THERAPEUTICS ReportS THIRD Quarter 2019 Results AND PROVIDES BUSINESS UPDATE New Data from Phase I/IIa Clinical Study of OpRegen Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last Visit Implemented Significant Additional Cost-Cutt
Read more →LCTXLINEAGE CELL THERAPEUTICS PRESENTS NEW OPREGEN DATA AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING Treatment with OpRegen Continues to be Well Tolerated with Increased Visual Acuity Observed in Cohort 4 Patients CAR
CELL THERAPEUTICS PRESENTS NEW OPREGEN DATA AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING with OpRegen Continues to be Well Tolerated with Increased Visual Acuity Observed in Cohort 4 Patients CA - October 14, 2019 - Lineage Cell Therapeutics, Inc. (NYSE American and TAS
Read more →LCTXLINEAGE CELL THERAPEUTICS RECEIVES CE MARK APPROVAL FOR RENEVIA Comparative clinical trial met its primary endpoint of change in hemifacial volume at six months (p .001) CARLSBAD, CA
CELL THERAPEUTICS RECEIVES CE MARK APPROVAL FOR RENEVIA clinical trial met its primary endpoint of change in hemifacial volume at six months (p<.001) CA - September 19, 2019 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology compan
Read more →LCTXBioTime ReportS SECOND Quarter 2019 Financial Results AND PROVIDES BUSINESS UPDATE Announced Rebranding and Name Change to Lineage Cell Therapeutics and Corporate Relocation Awarded $2.5 Million Grant from the Israel Inn
ReportS SECOND Quarter 2019 Financial Results AND Announced Rebranding and Name Change to Lineage Cell Therapeutics and Corporate Relocation Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen Conducted Sale of 2.25 Million
Read more →LCTXBioTime ReportS FIRST Quarter 2019 Financial Results AND PROVIDES BUSINESS UPDATE Positive OpRegen Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent fo
ReportS FIRST Quarter 2019 Financial Results AND PROVIDES Positive OpRegen Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Ent
Read more →LCTXBIOTIME presentS UPDATED DATA FROM OPREGEN PHASE i/IIA CLINICAL STUDY AT THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY ANNUAL MEETING Treatment with OpRegen Continues to be Well Tolerated with Signs of Structu
presentS UPDATED DATA FROM OPREGEN PHASE i/IIA CLINICAL STUDY AT THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY with OpRegen Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some CA - May 2, 2019 - BioTime, Inc. (NYSE Ameri
Read more →LCTXBIOTIME TO PRESENT SCiSTAR CLINICAL STUDY TOP-LINE DATA AT THE 26
TO PRESENT SCiSTAR CLINICAL STUDY TOP-LINE DATA AT THE 26TH ANNUAL AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR CONFERENCE CA - April 26, 2019 - BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced to
Read more →LCTXBioTime ReportS FOURTH Quarter AND FULL YEAR 2018 Financial Results AND PROVIDES BUSINESS UPDATE Completed Acquisition of Asterias Biotherapeutics, Inc. Completed Distribution of AgeX Therapeutics Shares to BioTime Share
ReportS FOURTH Quarter AND FULL YEAR 2018 Financial Results PROVIDES BUSINESS UPDATE Completed Acquisition of Asterias Biotherapeutics, Inc. Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders Entered Into Exclusive Collaboration with Orbit Biomedic
Read more →LCTXBIOTIME PROVIDES BUSINESS UPDATE including information ON agex, ONCOCYTE and
PROVIDES BUSINESS UPDATE including information ON agex, ONCOCYTE and ASTERIAS CA - February 14, 2019 - BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on Ag
Read more →LCTXBioTime and ASTERIAS BIOTHERAPEUTICS enter into definitive merger agreement TO CREATE leading cell therapy company BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in
and ASTERIAS BIOTHERAPEUTICS enter into definitive merger agreement TO CREATE leading cell therapy company Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology Stockholders to Receive 0.71 Share
Read more →LCTXBioTime ReportS Third Quarter 2018 Financial Results AND PROVIDES BUSINESS UPDATE Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from A
ReportS Third Quarter 2018 Financial Results AND PROVIDES BUSINESS UPDATE Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence Ltd. Positive OpRege
Read more →LCTXBIOTIME, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF JUNE 30, 2018 (IN THOUSANDS) BioTime, Inc. Consolidated, as Reported Pro Forma Adjustments for AgeX Therapeutics, Inc., Consolidat
INC. AND SUBSIDIARIES PRO FORMA CONDENSED COMBINED BALANCE SHEET BioTime, Inc. Consolidated, as Reported Pro Forma Adjustments for AgeX Therapeutics, Inc., Consolidated, and the Transaction Notes Pro Forma ASSETS CURRENT ASSETS Cash and cash
Read more →LCTXBioTime Reports Second Quarter Results and Recent Corporate Accomplishments BioTime to receive $43 million from Juvenescence BioTime shareholders to receive one share of AgeX common stock for every 10 shares of BioTime c
Reports Second Quarter Results and Recent Corporate Accomplishments to receive $43 million from Juvenescence shareholders to receive one share of AgeX common stock for every 10 shares of BioTime common stock held clinical programs including OpRegen for dry-AMD and Renevia f
Read more →LCTXBioTime Reports First Quarter Results and Recent Corporate Accomplishments Renevia CE Mark application successfully submitted for European approval OpRegen cohort 4 initiated in better-vision patients OpRegen data slides
Reports First Quarter Results and Recent Corporate Accomplishments CE Mark application successfully submitted for European approval cohort 4 initiated in better-vision patients data slides, conference call and webcast today at 1:30pm PT/4:30pm ET ALAMEDA, Calif.--(BUSINESS WI
Read more →LCTXBioTime Reports Fourth Quarter and Fiscal 2017 Results Renevia CE Mark application submitted for European approval OpRegen receives DSMB approval to proceed to cohort 4 OpRegen cohort 4 will include better vision patient
Reports Fourth Quarter and Fiscal 2017 Results CE Mark application submitted for European approval receives DSMB approval to proceed to cohort 4 cohort 4 will include better vision patients and an array of additional functional assessments ALAMEDA, Calif.--(BUSINESS WIRE)--M
Read more →LCTXBioTime Appoints Cavan Redmond to Its Board of Directors Former CEO of WebMD, former General Manager of Wyeth Biopharma and Group President of Pfizer 30 Years of Executive Management and Corporate Strategy Experience in
Appoints Cavan Redmond to Its Board of Directors CEO of WebMD, former General Manager of Wyeth Biopharma and Group President of Pfizer Years of Executive Management and Corporate Strategy Experience in ALAMEDA, Calif.--(BUSINESS WIRE)--February 22, 2018--BioTime, Inc. (NYSE
Read more →LCTXBioTime Reports Third Quarter Results and Recent Corporate Accomplishments Over $40M in recent funding Renevia advancing toward anticipated regulatory approval in Europe OpRegen advancing in clinical trials AgeX distribu
Reports Third Quarter Results and Recent Corporate Accomplishments $40M in recent funding advancing toward anticipated regulatory approval in Europe advancing in clinical trials distribution expected to be completed by early second quarter 2018 ALAMEDA, Calif.--(BUSINESS WIR
Read more →LCTXBioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia Pivotal Trial Filing for Renevia CE mark by the end of 2017 Positive long-term data in HIV-associated lipoatrophy reinforces Re
Announces Positive Secondary and Additional Positive Long-Term Data from CE mark by the end of 2017 long-term data in HIV-associated lipoatrophy reinforces Renevia's potential in multibillion-dollar global facial aesthetics market ALAMEDA, Calif.--(BUSINESS WIRE)--September 2
Read more →LCTXBioTime Reports Second Quarter Results and Recent Corporate Accomplishments Conference Call and Live Webcast 4.30pm Eastern Time Today ALAMEDA, Calif.--(BUSINESS WIRE)
BioTime Reports Second Quarter Results and Recent Corporate Accomplishments Conference Call and Live Webcast 4.30pm Eastern Time Today ALAMEDA, Calif.--(BUSINESS WIRE)--August 2, 2017--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commerci
Read more →LCTXBioTime's Renevia Achieves Primary Endpoint in European Pivotal Trial Data Reinforce Renevia's Potential in Multi-Billion Dollar Facial Aesthetics Market BioTime on Track to File for Renevia CE Mark by End of 2017 Confer
Renevia Achieves Primary Endpoint in European Pivotal Trial Reinforce Renevia's Potential in Multi-Billion Dollar Facial Aesthetics on Track to File for Renevia CE Mark by End of 2017 Call Today with Lead Investigator at 4:30 p.m. ET ALAMEDA, Calif.--(BUSINESS WIRE)--June 14,
Read more →LCTXBioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif--(BUSINESS WIRE)
Inc. Reports First Quarter Results and Recent Corporate Accomplishments Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif--(BUSINESS WIRE)--May 10, 2017--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializin
Read more →LCTXKey BioTime Patents Upheld by European Patent Office EPO Rules Patents for OpRegen are Valid and Remain in Force as Granted OpRegen is in Development to Treat Dry-AMD ALAMEDA, Calif.--(BUSINESS WIRE)
BioTime Patents Upheld by European Patent Office Valid and Remain in Force as Granted is in Development to Treat Dry-AMD ALAMEDA, Calif.--(BUSINESS WIRE)--March 28, 2017--BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing prod
Read more →LCTXBioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif.--(BUSINESS WIRE)--March 16, 2017--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology co
Read more →LCTXBioTime, Inc. Announces Closing of Public Offering of Common Stock ALAMEDA, CA, & JERUSALEM
BioTime, Inc. Announces Closing of Public Offering of Common Stock ALAMEDA, CA, & JERUSALEM, February 15, 2017 - BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announc
Read more →LCTXBioTime, Inc. Announces Pricing of Public Offering of Common Stock ALAMEDA, CA, & JERUSALEM
BioTime, Inc. Announces Pricing of Public Offering of Common Stock ALAMEDA, CA, & JERUSALEM, February 10, 2017 - BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announc
Read more →LCTXBioTime, Inc. Announces Proposed Public Offering of Common Stock ALAMEDA, CA, & JERUSALEM
BioTime, Inc. Announces Proposed Public Offering of Common Stock ALAMEDA, CA, & JERUSALEM, February 9, 2017 - BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced
Read more →LCTXBioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress Initial data from OpRegen trial suggest cells able to engraft and survive at least 12 months Initial 3-D Imaging data from Renevia trial run-in pat
Inc. Reports Third Quarter Results and Recent Clinical Progress trial suggest cells able to engraft and survive at least 12 months 3-D Imaging data from Renevia trial run-in patients suggest volumetric improvements are sustained at least 12 months ALAMEDA, Calif.--(BUSINESS W
Read more →LCTXBioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments Therapeutic Candidates Continue Clinical Progress Deconsolidation Simplifies Financials Successful Public Equity Offering Strengthens Bala
Inc. Reports Second Quarter Results and Recent Corporate Accomplishments Candidates Continue Clinical Progress Simplifies Financials Public Equity Offering Strengthens Balance Sheet ALAMEDA, Calif.--(BUSINESS WIRE)--August 9, 2016--BioTime, Inc. (NYSE MKT:BTX), a clinical-st
Read more →LCTXBioTime, Inc. Announces Full Exercise and Closing of Underwriters' Over-Allotment Option ALAMEDA, Calif.--(BUSINESS WIRE)
BioTime, Inc. Announces Full Exercise and Closing of Underwriters' Over-Allotment Option ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 5, 2016--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field o
Read more →LCTXBioTime, Inc. Announces Pricing of Public Offering of Common Stock ALAMEDA, CA
BioTime, Inc. Announces Pricing of Public Offering of Common Stock ALAMEDA, CA, June 16, 2016 - BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced
Read more →LCTXBioTime, Inc. Announces Proposed Public Offering of Common Stock ALAMEDA, CA
BioTime, Inc. Announces Proposed Public Offering of Common Stock ALAMEDA, CA, June 15, 2016 - BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced it
Read more →LCTXC O R P O R A T E P A R T I C I P A N T S Dan L. Lawrence, Director, Investor Relations & Corporate Communications Adi Mohanty, Co-Chief Executive Officer Michael D. West, Ph.D., Co-Chief Executive Officer Russell Skibst
C O R P O R A T E P A R T I C I P A N T S Dan L. Lawrence, Director, Investor Relations & Corporate Communications Adi Mohanty, Co-Chief Executive Officer Michael D. West, Ph.D., Co-Chief Executive Officer Russell Skibsted, Chief Financial Officer C O N F E R E N C E C A L L
Read more →LCTXBioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments - First Cohort in OpRegen Trial Completed - Management to Host Investor Conference Call on
Inc. Reports First Quarter Results and Recent Corporate Accomplishments First Cohort in OpRegen Management to Host Investor Conference Call on May 17, 2016 at 4:30 p.m. ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2016--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage re
Read more →LCTXBioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents FREMONT, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)
BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents FREMONT, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 16, 2016--Asterias Biotherapeutics, Inc. (NYSE MKT: AST) and BioTime, Inc. (NYSE MKT and TASE: BTX),
Read more →LCTXBioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock Regular Way Trading of OncoCyte common stock on NYSE MKT to begin
Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock Way Trading of OncoCyte common stock on NYSE MKT to begin January 4, 2016 ALAMEDA, Calif.--(BUSINESS WIRE)--December 31, 2015--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage rege
Read more →LCTXBioTime Announces "When-Issued" Trading of Subsidiary OncoCyte Corporation in Connection With Planned Distribution ALAMEDA, Calif.--(BUSINESS WIRE)
Announces "When-Issued" Trading of Subsidiary OncoCyte Corporation in Connection With Planned Distribution ALAMEDA, Calif.--(BUSINESS WIRE)--December 30, 2015--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell
Read more →LCTXBioTime, Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of Shares of Subsidiary OncoCyte Corporation ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of Shares of Subsidiary OncoCyte Corporation ALAMEDA, Calif.--(BUSINESS WIRE)--December 11, 2015--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with
Read more →LCTXBioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer ALAMEDA, Calif.--(BUSINESS WIRE)--November 18, 2015--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent
Read more →LCTXBioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Reports Third Quarter 2015 Results and Recent Corporate ALAMEDA, Calif.--(BUSINESS WIRE)--November 9, 2015--BioTime, Inc. (NYSE MKT and TASE:BTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its recent "During
Read more →LCTXBioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro Cell Biology Market Combination of BioTime's ESI BIO Division and Hepregen to Focus on Next-Generation Metabolism and Saf
Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to of BioTime's ESI BIO Division and Hepregen to Focus on Next-Generation Metabolism and Safety Screening of New Drugs and Chemicals Access to Hepregen's Current Customer Base of Major Pharmaceutical and Retain
Read more →LCTXBioTime's Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned Distribution BioTime Plans Distribution of Shares of Subsidiary OncoCyte Corporation to BioTime Shareholders Planned Distribution
Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned Distribution Plans Distribution of Shares of Subsidiary OncoCyte Corporation to BioTime Shareholders Distribution to Allow OncoCyte Greater Access to Capital Markets as a Publicly Traded Company
Read more →LCTXBioTime, Inc. Agrees to Sell $5.1 Million of Equity ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Agrees to Sell $5.1 Million of Equity ALAMEDA, Calif.--(BUSINESS WIRE)--October 2, 2015--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it has agreed to sell 1,
Read more →LCTXHeraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements Agreements Provide for the Development of an Innovative Cell Therapy Product for Bone
Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements Provide for the Development of an Innovative Cell Therapy Product for Bone Grafting in Orthopedic Unmet Needs Medical to Fund All Product Development
Read more →LCTXBioTime's Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen for the Treatment of the Dry Form of Age-Related Macular Degeneration ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)
Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen for the Treatment of the Dry Form of Age-Related Macular Degeneration ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--September 28, 2015--BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsi
Read more →LCTXBioTime, Inc. Agrees to Sell Up to $20.7 Million of Common Shares Shares to be sold to TASE Index Funds in Israel
BioTime, Inc. Agrees to Sell Up to $20.7 Million of Common Shares Shares to be sold to TASE Index Funds in Israel ALAMEDA, Calif., September 25, 2015 - BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell up to $20.7 million of its common shares in
Read more →LCTXBioTime, Inc. Agrees to Sell $8.58 Million of Common Shares ALAMEDA, Calif., - (BUSINESS WIRE)
BioTime, Inc. Agrees to Sell $8.58 Million of Common Shares ALAMEDA, Calif., - (BUSINESS WIRE) - September 14, 2015 - BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell 2,607,401 of its common shares, no par value, at an offering price of $3.29 per
Read more →LCTXThe Wistar Institute and BioTime Subsidiary OncoCyte Corporation Expand Agreement to Develop Molecular Diagnostic Test for the Detection of Lung Cancer Agreement provides for continued development of a liquid biopsy test
Wistar Institute and BioTime Subsidiary OncoCyte Corporation Expand Agreement to Develop Molecular Diagnostic Test for the Detection of Lung provides for continued development of a liquid biopsy test designed to aid physicians in the early, non-invasive detection of lung cance
Read more →LCTXBioTime, Inc. Reports Second Quarter 2015 Results and Recent Developments ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Reports Second Quarter 2015 Results and Recent Developments ALAMEDA, Calif.--(BUSINESS WIRE)--August 10, 2015--BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the second quarter ended June 30, 2015 and provided a corporate update. "BioTime's management
Read more →LCTXBioTime Announces the Issuance of 27 New Patents Protecting Stem Cell-Based Product Development New patents add to existing portfolio of over 700 issued and pending patents and patent applications world wide owned or lic
Announces the Issuance of 27 New Patents Protecting Stem Cell-Based patents add to existing portfolio of over 700 issued and pending patents and patent applications world wide owned or licensed to BioTime or its subsidiaries ALAMEDA, Calif.--(BUSINESS WIRE)--August 10, 2015--
Read more →LCTXOncoCyte's Collaborators at The Wistar Institute Present Positive Clinical Interim Results of Blood-Based Diagnostic Test for Non-Invasive Detection of Lung Cancer Data Presented at the 2015 American Thoracic Society Int
Collaborators at The Wistar Institute Present Positive Clinical Interim Results of Blood-Based Diagnostic Test for Non-Invasive Detection of Presented at the 2015 American Thoracic Society International Conference ALAMEDA, Calif.--(BUSINESS WIRE)--May 19, 2015--BioTime, Inc. (
Read more →LCTXOncoCyte Corporation Completes Equity Financing Round - Capital to fund further development and commercialization efforts of cancer diagnostic tests by BioTime subsidiary - ALAMEDA, Calif.--(BUSINESS WIRE)
Corporation Completes Equity Financing Round to fund further development and commercialization efforts of cancer diagnostic tests by BioTime subsidiary - ALAMEDA, Calif.--(BUSINESS WIRE)--May 14, 2015--BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today
Read more →LCTXBioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel's Office of the Chief Scientist ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)
Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel's Office of the Chief Scientist ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--May 13, 2015--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced
Read more →LCTXBioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Reports First Quarter 2015 Results and Recent Corporate ALAMEDA, Calif.--(BUSINESS WIRE)--May 11, 2015--BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. "BioTime continues to advance
Read more →LCTXCell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen Preserves Vision Data to be Presented at Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting ALAMEDA, Calif. &
Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen to be Presented at Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--May 4, 2015--BioTime, Inc. (NYSE MKT: BTX) and its subsidia
Read more →LCTXLEADING THEREGENERATIVE MEDICINE REVOLUTION May 2015NYSE MKT: BTX The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that co
LEADING THEREGENERATIVE MEDICINE REVOLUTION May 2015NYSE MKT: BTX The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the resu
Read more →LCTXNovel Strategies for the Scalable Manufacture of Cellular Therapeutics from Pluripotent Stem Cells: Commercial Implications GTCbio 4th Stem CellProduct Development &Commercialization April 29 2015 Safe Harbor Statement 2
Novel Strategies for the Scalable Manufacture of Cellular Therapeutics from Pluripotent Stem Cells: Commercial Implications GTCbio 4th Stem CellProduct Development &Commercialization April 29 2015 Safe Harbor Statement 2 The matters discussed in this presentation include forward
Read more →LCTXBioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington's Disease ALAMEDA, Calif.--(BUSINESS WIRE)
Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington's Disease ALAMEDA, Calif.--(BUSINESS WIRE)--April 27, 2015--BioTime, Inc. (NYSE MKT:BTX) today announced that the clinical-grade human Embryonic
Read more →LCTXHUMAN EMBRYONIC STEM CELL-DERIVED CLONAL BROWN ADIPOCYTE PROGENITORS Hal Sternberg, David Larocca, Michael D. WestBioTime, Inc., Alameda, CA, USA ABSTRACTEmerging strategies for the treatment of metabolic disorders via t
HUMAN EMBRYONIC STEM CELL-DERIVED CLONAL BROWN ADIPOCYTE PROGENITORS Hal Sternberg, David Larocca, Michael D. WestBioTime, Inc., Alameda, CA, USA ABSTRACTEmerging strategies for the treatment of metabolic disorders via the transplantation of brown adipose tissue (BAT) cells will
Read more →LCTXPositive Clinical Results of OncoCyte's PanC-Dx Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer Data Presented at American Association for Cancer Research
Clinical Results of OncoCyte's PanC-Dx Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer Presented at American Association for Cancer Research 2015 Annual Meeting ALAMEDA, Calif.--(BUSINESS WIRE)--April 20, 2015-
Read more →LCTXLifeMap Solutions and Mount Sinai - National Jewish Health Respiratory Institute Launch Pilot Program of COPD Navigator App App for Patients is First Component of Broader Chronic-Condition Platform that Integrates with "
Solutions and Mount Sinai - National Jewish Health Respiratory Institute Launch Pilot Program of COPD Navigator App for Patients is First Component of Broader Chronic-Condition Platform that Integrates with "Smart" Inhaler Technology and Clinician Dashboard SAN JOSE, Calif.--
Read more →LCTXOncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx Cancer Diagnostic in Bladder and Breast Cancer Data to be Presented at American Association for Cancer Research 2015 Annual Meet
Announces Availability of Abstracts With New Clinical Data From Studies Cancer Diagnostic in Bladder and Breast Cancer to be Presented at American Association for Cancer Research 2015 Annual ALAMEDA, Calif.--(BUSINESS WIRE)--March 20, 2015--BioTime, Inc. (NYSE MKT:BTX) and it
Read more →LCTXBioTime, Inc. Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)--March 11, 2015--BioTime, Inc. (NYSE MKT: BTX) today reported financial results for the quarter and year ended December 31, 2014, and h
Read more →LCTXIcahn School of Medicine at Mount Sinai and LifeMap Solutions Launch Asthma Study for iPhone First-of-its-kind asthma study developed using ResearchKit framework NEW YORK--(BUSINESS WIRE)
School of Medicine at Mount Sinai and LifeMap Solutions Launch Asthma asthma study developed using ResearchKit framework NEW YORK--(BUSINESS WIRE)--March 9, 2015--The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a subsidiary of BioTime (NYSE MKT:BTX), today
Read more →LCTXBioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia for HIV-Associated Lipoatrophy ALAMEDA, Calif.--(BUSINESS WIRE)
Announces First Patient Treated in Pivotal Clinical Trial of Renevia for HIV-Associated Lipoatrophy ALAMEDA, Calif.--(BUSINESS WIRE)--February 24, 2015--BioTime, Inc. (NYSE MKT: BTX) today announced that the first patient was successfully treated in the Company's pivotal clin
Read more →LCTXLeading the Revolution in Regenerative Medicine NYSE MKT: BTX February, 2015 Safe Harbor Statement * The matters discussed in this presentation include forward looking statements which are subject to various risks, uncer
Leading the Revolution in Regenerative Medicine NYSE MKT: BTX February, 2015 Safe Harbor Statement * The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results
Read more →LCTXOncoCyte to Present Cancer Diagnostic Clinical Study Data at AACR Annual Meeting - BioTime subsidiary's data collected from prospective clinical studies in bladder and breast cancer - ALAMEDA, Calif.--(BUSINESS WIRE)
to Present Cancer Diagnostic Clinical Study Data at AACR Annual Meeting subsidiary's data collected from prospective clinical studies in bladder ALAMEDA, Calif.--(BUSINESS WIRE)--February 6, 2015--BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today annou
Read more →LCTXSUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this " Agreement ") is made as of
SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this "Agreement") is made as of February 4, 2015 by and between Asterias Biotherapeutics, Inc., a Delaware corporation (the "Company"), and the investor listed on Schedule A hereto (each, an "Investor" and together, the "Invest
Read more →LCTXBioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy ALAMEDA, Calif.--(BUSINESS WIRE)--January 26, 2015--BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the
Read more →LCTXBioTime Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)
Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of ALAMEDA, Calif.--(BUSINESS WIRE)--January 12, 2015--BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that William Annett has been appointed to OncoCyte's Board of Direct
Read more →LCTXRegenerative Medicine Through PluripotencyNYSE MKT: BTX January, 2015 Safe Harbor Statement 2 The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertaintie
Regenerative Medicine Through PluripotencyNYSE MKT: BTX January, 2015 Safe Harbor Statement 2 The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to dif
Read more →LCTXBioTime Appoints Adi Mohanty Chief Operating Officer Executive Brings Proven Leadership in Biopharmaceutical Product Development and Commercialization to BioTime ALAMEDA, Calif.--(BUSINESS WIRE)
Appoints Adi Mohanty Chief Operating Officer Brings Proven Leadership in Biopharmaceutical Product Development and Commercialization to BioTime ALAMEDA, Calif.--(BUSINESS WIRE)--December 29, 2014--BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell ther
Read more →LCTXBioTime Appoints Angus C. Russell to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)
Appoints Angus C. Russell to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)--December 15, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Angus C. Russell, former
Read more →LCTXBioTime to Host Investor and Analyst Day on
to Host Investor and Analyst Day on December 15, 2014 ALAMEDA, Calif.--(BUSINESS WIRE)--December 12, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced today that it will host its In
Read more →LCTXBioTime to Present at the LD Micro VII Conference ALAMEDA, Calif.--(BUSINESS WIRE)
to Present at the LD Micro VII Conference ALAMEDA, Calif.--(BUSINESS WIRE)--December 3, 2014--BioTime, Inc. (NYSE MKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D
Read more →LCTXBioTime Reports Third Quarter Results and Recent Progress Asterias Biotherapeutics approved for listing on NYSE MKT Asterias' AST-OPC1 cleared by FDA for Phase 1/2a dose escalation clinical trial for spinal cord injury C
Reports Third Quarter Results and Recent Progress Biotherapeutics approved for listing on NYSE MKT AST-OPC1 cleared by FDA for Phase 1/2a dose escalation clinical trial for spinal cord injury Cure Neuroscience's OpRegen cleared by FDA for Phase 1/2a dose escalation clinical
Read more →LCTXShareholder UpdateThe RegenerativeMedicine Revolution
Shareholder UpdateThe RegenerativeMedicine Revolution November 4, 2014 Safe Harbor Statement The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to diff
Read more →LCTXBioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia in Europe Renevia to be utilized in the treatment of HIV-related lipoatrophy, a disorder estimated to afflict more than 3.5 million patients
Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia to be utilized in the treatment of HIV-related lipoatrophy, a disorder estimated to afflict more than 3.5 million patients globally enrollment initiated; expected to be completed in 2015 ALAMEDA, Calif.--
Read more →LCTXBioTime's Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen for the Treatment of the Dry Form of Age-Related Macular Degeneration IND clear
Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen for the Treatment of the Dry Form of Age-Related Macular Degeneration cleared for Phase I/IIa dose escalation trial in patients with the dry form
Read more →LCTXBioTime, Inc. Closes $31 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Closes $31 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)--October 9, 2014--BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries rece
Read more →LCTXMichael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)
H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)--October 6, 2014--BioTime, Inc. (NYSE MKT:BTX) announced today that Michael H. Mulroy and Stephen L. Cartt are joining its Board of Directors. Mr. Mulroy has been appointed to th
Read more →LCTXBioTime's Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Institute - Final Study Enrollment Exceeds 600 Patients - ALAMEDA, Cali
Subsidiary OncoCyte Corporation Announces Completion of Multi-Site Clinical Study of Lung Cancer Diagnostic by Collaborators at The Wistar Study Enrollment Exceeds 600 Patients - ALAMEDA, Calif.--(BUSINESS WIRE)--October 3, 2014--BioTime, Inc. (NYSE MKT: BTX), and its subsidi
Read more →LCTXLifeMap Solutions Adds Chief Technology Officer to Leadership Team Additional Experts from Partner Icahn Institute at Mount Sinai Form Science Team ALAMEDA, Calif.--(BUSINESS WIRE)
Solutions Adds Chief Technology Officer to Leadership Team Experts from Partner Icahn Institute at Mount Sinai Form Science Team ALAMEDA, Calif.--(BUSINESS WIRE)--October 1, 2014--BioTime, Inc. (NYSE MKT:BTX) and its subsidiary LifeMap Solutions, Inc., a medical technology co
Read more →LCTXJoseph Wagner, Ph.D. Chief Executive Officer
Joseph Wagner, Ph.D. Chief Executive OfficerSeptember 25, 2014 OncoCyte Corporation * Our mission is to develop novel products for the diagnosis and treatment of cancer in order to improve both the quality and length of life of cancer patients Internally developed cancer gene di
Read more →LCTXBioTime, Inc.'s Subsidiary OncoCyte Corporation's CEO Dr. Joseph Wagner to Present at BTIG's Inaugural "Emerging Technologies in Healthcare Diagnostics" Symposium ALAMEDA, Calif.--(BUSINESS WIRE)
Inc.'s Subsidiary OncoCyte Corporation's CEO Dr. Joseph Wagner to Present at BTIG's Inaugural "Emerging Technologies in Healthcare Diagnostics" Symposium ALAMEDA, Calif.--(BUSINESS WIRE)--September 19, 2014--OncoCyte Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
Read more →LCTXBioTime's Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and Efficacy of OpRegen in Preclinical Animal Studies ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)
Subsidiary Cell Cure Neurosciences Ltd. Demonstrates the Safety and in Preclinical Animal Studies ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--September 17, 2014--BioTime, Inc. (NYSE MKT: BTX), HBL Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange: HDST) and Cell Cure Neuro
Read more →LCTXBioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer ALAMEDA, Calif.--(BUSINESS WIRE)
Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine ALAMEDA, Calif.--(BUSINESS WIRE)--September 11, 2014--BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherape
Read more →LCTXNYSE MKT: BTX Rodman & Renshaw16th Annual GlobalInvestment Conference
NYSE MKT: BTX Rodman & Renshaw16th Annual GlobalInvestment ConferenceSeptember 10, 2014 Safe Harbor Statement * The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause act
Read more →LCTXBioTime CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Dr. Michael D. West to Present at Rodman & Renshaw 16th Annual Healthcare Conference ALAMEDA, Calif.--(BUSINESS WIRE)--September 9, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today
Read more →LCTXBioTime to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem -Based Hydrogel for Vocal Fold Scarring Investigator-initiated clinical trial may follow preclinical studies ALAMEDA, Calif
to Collaborate With the University of Wisconsin and Louvain University in Test of HyStem -Based Hydrogel for Vocal Fold Scarring Investigator-initiated clinical trial may follow preclinical studies ALAMEDA, Calif.--(BUSINESS WIRE)--August 28, 2014--BioTime, Inc. (NYSE MKT:B
Read more →LCTXBioTime Receives FDA Premarket Notification Clearance for Premvia 510(k) ALAMEDA, Calif.--(BUSINESS WIRE)
Receives FDA Premarket Notification Clearance for Premvia ALAMEDA, Calif.--(BUSINESS WIRE)--August 12, 2014--BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA's Center for Devices and Radiologic Health that Premvia has been cleared for mar
Read more →LCTXBioTime Announces Second Quarter 2014 Results and Recent Developments Three cancer diagnostic products in clinical development IND amendment pending for expanded clinical trials of AST-OPC1 Asterias obtains over $12 mill
Announces Second Quarter 2014 Results and Recent Developments cancer diagnostic products in clinical development amendment pending for expanded clinical trials of AST-OPC1 obtains over $12 million in financing and awarded a $14 million grant provides 510(k) premarket clearanc
Read more →LCTXBioTime, Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial - PanC-Dx Markers to be Tested on Over 1,000 Patient Samples from Ur
Inc. Subsidiary OncoCyte Corporation Expands Clinical Development of Bladder Cancer Diagnostic by Initiating a Large Multi-Site Clinical Trial to be Tested on Over 1,000 Patient Samples from Urology Clinics Located Throughout United States- ALAMEDA, Calif.--(BUSINESS WIRE)--J
Read more →LCTXBioTime Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy - New issued patents add to existing estate of over 600 patents and patent applications worldwide in the e
Announces Issuance of 14 Patents in the Fields of Regenerative Medicine, and Cancer Diagnosis and Therapy issued patents add to existing estate of over 600 patents and patent applications worldwide in the emerging field of pluripotent stem cell ALAMEDA, Calif.--(BUSINESS WIRE
Read more →LCTXBioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing Capital infusion provides funding to advance Asterias' therapeutic programs Substantially strengthens Asterias' cash position ALAMEDA,
Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity infusion provides funding to advance Asterias' therapeutic programs strengthens Asterias' cash position ALAMEDA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--June 17, 2014--BioTime, Inc. (NYSE MKT: BTX) annou
Read more →LCTXBioTime Subsidiary Asterias Biotherapeutics Announces Investment by CEO CEO Pedro Lichtinger purchases 200,000 shares of Asterias Series B common stock ALAMEDA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)
Subsidiary Asterias Biotherapeutics Announces Investment by CEO Pedro Lichtinger purchases 200,000 shares of Asterias Series B common ALAMEDA, Calif. & MENLO PARK, Calif.--(BUSINESS WIRE)--June 17, 2014--BioTime, Inc. (NYSE MKT: BTX) today announced that on June 12, 2014, Ped
Read more →LCTXBioTime Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger as President and Chief Executive Officer Pharmaceutical and Biotechnology Industry Professional with 35 Years of Experi
Subsidiary Asterias Biotherapeutics Appoints Former Pfizer Senior Executive Pedro Lichtinger as President and Chief Executive Officer and Biotechnology Industry Professional with 35 Years of Experience Track Record of Successful Drug Development and Commercialization on Advan
Read more →LCTXBioTime to Present at the Jefferies 2014 Global Healthcare Conference ALAMEDA, Calif.--(BUSINESS WIRE)
to Present at the Jefferies 2014 Global Healthcare Conference ALAMEDA, Calif.--(BUSINESS WIRE)--June 2, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive
Read more →LCTXBioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnership Award from the California Institute for Regenerative Medicine Award Supports Phase 1/2a Dose Escalation Clinical Trial o
Subsidiary Asterias Biotherapeutics, Inc. Announces a $14.3 Million Strategic Partnership Award from the California Institute for Regenerative Medicine Supports Phase 1/2a Dose Escalation Clinical Trial of AST-OPC1 in Cervical Spinal Cord Injury Provides for the Expansion of
Read more →LCTXBioTime's Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)
Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--May 28, 2014--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias Biotherapeutics, Inc. ("Asterias"), announced that Asterias has entered into a
Read more →LCTXBioTime Receives ISO 13485 Certification for Medical Devices ALAMEDA, Calif.--(BUSINESS WIRE)
Receives ISO 13485 Certification for Medical Devices ALAMEDA, Calif.--(BUSINESS WIRE)--May 28, 2014--BioTime, Inc. (NYSE MKT: BTX) today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture,
Read more →LCTXBioTime's Subsidiary OncoCyte Corporation and Cornell University Enter License Agreement to Accelerate Lung Cancer Diagnostic Product Development - PanC-Dx Markers to be Tested in Patient Samples Collected by Investigato
Subsidiary OncoCyte Corporation and Cornell University Enter License Agreement to Accelerate Lung Cancer Diagnostic Product Development to be Tested in Patient Samples Collected by Investigators at Weill-Cornell Medical Center - ALAMEDA, Calif.--(BUSINESS WIRE)--May 27, 2014-
Read more →LCTXAsterias Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com BioTime, Inc. Subsidiary Acquired Geron Corp's Therapeutic Stem Cell Assets in Oct. 2013 MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WI
Biotherapeutics, Inc. Launches New Website: Asteriasbiotherapeutics.com Inc. Subsidiary Acquired Geron Corp's Therapeutic Stem Cell Assets in MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--May 21, 2014--Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (N
Read more →LCTXAsterias Biotherapeutics, Inc. to Present Phase I Clinical Data at the 17th Annual Meeting of the American Society of Gene & Cell Therapy ALAMEDA, Calif.--(BUSINESS WIRE)
Biotherapeutics, Inc. to Present Phase I Clinical Data at the 17th Annual Meeting of the American Society of Gene & Cell Therapy ALAMEDA, Calif.--(BUSINESS WIRE)--May 13, 2014--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Asterias Biotherapeutics, Inc. today announced tha
Read more →LCTXBioTime Announces First Quarter 2014 Results and Recent Developments Four products currently in clinical development Three therapeutic products currently in late-stage preparation for clinical development Shares of Aster
Announces First Quarter 2014 Results and Recent Developments products currently in clinical development therapeutic products currently in late-stage preparation for clinical of Asterias subsidiary scheduled to trade publicly in near term Solutions subsidiary launched to devel
Read more →LCTXLifeMap Solutions, Inc. to Develop Mobile Health Products With Mount Sinai's Icahn School of Medicine ALAMEDA, Calif.--(BUSINESS WIRE)
Solutions, Inc. to Develop Mobile Health Products With Mount Sinai's Icahn School of Medicine ALAMEDA, Calif.--(BUSINESS WIRE)--May 7, 2014--BioTime, Inc. (NYSE MKT:BTX) announced today that its subsidiary LifeMap Sciences, Inc., a technology leader in online biomedical infor
Read more →LCTXBioTime Raises $6.4 Million in Equity Financing ALAMEDA, Calif.--(BUSINESS WIRE)
Raises $6.4 Million in Equity Financing ALAMEDA, Calif.--(BUSINESS WIRE)--May 5, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that on May 1, 2014, the Company received ap
Read more →LCTXBioTime to Present at GTC Stem Cell Summit 2014 ALAMEDA, Calif.--(BUSINESS WIRE)
to Present at GTC Stem Cell Summit 2014 ALAMEDA, Calif.--(BUSINESS WIRE)--April 24, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. W
Read more →LCTXBioTime, Inc. Announces Board Membership Changes and Management and Board Changes at Its Subsidiary Asterias Biotherapeutics, Inc. ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Announces Board Membership Changes and Management and Board Changes at Its Subsidiary Asterias Biotherapeutics, Inc. ALAMEDA, Calif.--(BUSINESS WIRE)--April 14, 2014--BioTime, Inc. (NYSE MKT: BTX) announced that its Board of Directors has appointed Deborah Andrews and Da
Read more →LCTXBioTime to Present at 13 th Annual Needham Healthcare Conference ALAMEDA, Calif.--(BUSINESS WIRE)
Annual Needham Healthcare Conference ALAMEDA, Calif.--(BUSINESS WIRE)--April 7, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West,
Read more →LCTXBioTime To Present at Regen Med Investor Day March 26 in New York ALAMEDA, Calif.--(BUSINESS WIRE)
To Present at Regen Med Investor Day March 26 in New York ALAMEDA, Calif.--(BUSINESS WIRE)--March 25, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Of
Read more →LCTXBioTime Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)--March 17, 2014--BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2013 a
Read more →LCTXBioTime Raises $3.5 Million Through Preferred Stock Offering ALAMEDA, Calif.--(BUSINESS WIRE)
Raises $3.5 Million Through Preferred Stock Offering ALAMEDA, Calif.--(BUSINESS WIRE)--March 5, 2014--BioTime, Inc. (NYSE MKT: BTX) today announced it has sold 70,000 shares of a newly authorized Series A Convertible Preferred Stock for $3.5 million. The Series A Preferred St
Read more →LCTXBioTime Provides Financing and Product Development Update $12.6 Million Raised Since
Provides Financing and Product Development Update Since October 1, 2013 in At-the-Market Stock Sales is Awarded New NIH SBIR Grant 510(k) Premarket Notification Submitted to FDA for Review ALAMEDA, Calif.--(BUSINESS WIRE)--March 3, 2014--BioTime, Inc. (NYSE MKT: BTX) today a
Read more →LCTXBioTime CEO Dr. Michael West to Present at 9 th Annual Stem Cell Summit ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Dr. Michael West to Present at 9th Annual Stem Cell Summit ALAMEDA, Calif.--(BUSINESS WIRE)--February 18, 2014--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Exec
Read more →LCTXBioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development of Bladder Cancer Diagnostics in the United States and China - PanC-Dx Markers to be Tested Include Those Recently Awarded Patent Protection -
Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development of Bladder Cancer Diagnostics in the United States and China to be Tested Include Those Recently Awarded Patent Protection - ALAMEDA, Calif.--(BUSINESS WIRE)--January 27, 2014--BioTime, Inc. (NYSE MKT: BTX) a
Read more →LCTXBioTime's Subsidiary LifeMap Sciences Announces Release of LifeMap Discovery Version 1.5 with GeneAnalytics , a Powerful Gene Expression Analysis Tool ALAMEDA, Calif.--(BUSINESS WIRE)
Subsidiary LifeMap Sciences Announces Release of LifeMap Version 1.5 with GeneAnalytics , a Powerful Gene Expression Analysis Tool ALAMEDA, Calif.--(BUSINESS WIRE)--January 17, 2014--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the r
Read more →LCTXBioTime Reports Results of Clinical Safety Trial of Renevia Renevia Appears Safe And Well Tolerated With No Serious Unexpected Adverse Events Observed During The Trial Period Manufacturing and Biocompatibility Informatio
Reports Results of Clinical Safety Trial of Renevia Appears Safe And Well Tolerated With No Serious Unexpected Adverse Events Observed During The Trial Period and Biocompatibility Information Submitted in a Device Master File to ALAMEDA, Calif.--(BUSINESS WIRE)--January 13, 2
Read more →LCTXAsterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases Facilities for Expanded Product Development and Manufacturing MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)
Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases Facilities for Expanded Product Development and Manufacturing MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--January 2, 2014--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) today announced
Read more →LCTXBioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel's Office of the Chief Scientist ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)
Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel's Office of the Chief Scientist ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--December 23, 2013--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today anno
Read more →LCTXBioTime Reports Isolation of Novel Brain-Associated Cells From Human Embryonic Stem Cells ALAMEDA, Calif.--(BUSINESS WIRE)
Reports Isolation of Novel Brain-Associated Cells From Human Embryonic ALAMEDA, Calif.--(BUSINESS WIRE)--December 20, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine reported today the public
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards Version 3.11 New Release Features showcasing of gene-relevant scientific conferences ALAMEDA, Calif.--(BUSINESS WIRE)
Sciences, a Subsidiary of BioTime, Announces Release of GeneCards Release Features showcasing of gene-relevant scientific conferences ALAMEDA, Calif.--(BUSINESS WIRE)--December 6, 2013--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the
Read more →LCTXBioTime's CEO, Dr. Michael West to Moderate Session on Mapping the Cellular Basis of Life at the 2013 World Stem Cell Summit ALAMEDA, Calif.--(BUSINESS WIRE)
CEO, Dr. Michael West to Moderate Session on Mapping the Cellular Basis of Life at the 2013 World Stem Cell Summit ALAMEDA, Calif.--(BUSINESS WIRE)--December 4, 2013--BioTime, Inc. (NYSE MKT: BTX) and subsidiary, LifeMap Sciences, announced that BioTime's CEO, Dr. Michael Wes
Read more →LCTXAsterias Biotherapeutics, Inc. Files Registration Statement for Underwritten Public Offering MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)
Biotherapeutics, Inc. Files Registration Statement for Underwritten MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--December 2, 2013--Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that Asterias has filed a registration s
Read more →LCTXBioTime CEO Dr. Michael West to Present at 11 th Annual Commercial Translation of Regenerative Medicine Conference ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference ALAMEDA, Calif.--(BUSINESS WIRE)--November 25, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerativ
Read more →LCTXBioTime Announces Third Quarter 2013 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Third Quarter 2013 Financial Results and Recent Corporate ALAMEDA, Calif.--(BUSINESS WIRE)--November 12, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial re
Read more →LCTXBioTime, Inc. to Provide Company Updates During Investor Day
Inc. to Provide Company Updates During Investor Day, October 28, 2013 ALAMEDA, Calif.--(BUSINESS WIRE)--October 28, 2013--BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York Cit
Read more →LCTXBioTime Reports Interim Results on Renevia Clinical Safety Trial - Enrollment completed in first safety study of Renevia for dermatological applications - - Two weeks following administration, Renevia appears safe and we
Reports Interim Results on Renevia Clinical Safety Trial Enrollment completed in first safety study of Renevia for dermatological applications - weeks following administration, Renevia appears safe and well tolerated with no serious unexpected adverse events observed to dat
Read more →LCTXBioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company's Cell-Based Research Products Appoints Jeffrey Janus as CEO of ES Cell International Pte Ltd. ALAMEDA, Calif.--(BUSINESS WIRE)
Organizes New ESI BIO Division to Develop, Manufacture and Market the Company's Cell-Based Research Products Jeffrey Janus as CEO of ES Cell International Pte Ltd. ALAMEDA, Calif.--(BUSINESS WIRE)--October 28, 2013--BioTime, Inc. (NYSE MKT: BTX) today announced changes to the
Read more →LCTXBioTime Announces Additional Products in Development Based on HyStem Technology ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Additional Products in Development Based on HyStem ALAMEDA, Calif.--(BUSINESS WIRE)--October 4, 2013--BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem hydrogel technology platform. The firs
Read more →LCTXBioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem Technology ALAMEDA, Calif.--(BUSINESS WIRE)
Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem ALAMEDA, Calif.--(BUSINESS WIRE)--September 19, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative me
Read more →LCTXBioTime Receives Approval to Begin Human Clinical Trials of Renevia ALAMEDA, Calif.--(BUSINESS WIRE)
Receives Approval to Begin Human Clinical Trials of Renevia ALAMEDA, Calif.--(BUSINESS WIRE)--August 28, 2013--BioTime, Inc. (NYSE MKT: BTX) today announced that it has received approval from The Spanish Agency of Medicines and Medical Devices (AEMPS) to begin human clinical
Read more →LCTXBioTime Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development ALAMEDA, Calif.--(BUSINESS WIRE)
Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development ALAMEDA, Calif.--(BUSINESS WIRE)--August 21, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, t
Read more →LCTXBioTime Announces Second Quarter 2013 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Second Quarter 2013 Financial Results and Recent Corporate ALAMEDA, Calif.--(BUSINESS WIRE)--August 9, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial resu
Read more →LCTXBioTime's Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker - FSIP1 is one component of a panel of markers comprising PanC-Dx TM , a blood-based cancer screen - ALAMEDA,
Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker is one component of a panel of markers comprising PanC-DxTM, a blood-based cancer screen - ALAMEDA, Calif.--(BUSINESS WIRE)--August 5, 2013--BioTime, Inc. (NYSE MKT: BTX) and
Read more →LCTXBioTime CEO Dr. Michael West to Present at the Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Dr. Michael West to Present at the Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course ALAMEDA, Calif.--(BUSINESS WIRE)--July 16, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the
Read more →LCTXBioTime Appoints Henry L. Nordhoff to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)
Appoints Henry L. Nordhoff to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)--June 12, 2013--BioTime, Inc. (NYSE MKT: BTX) today announced that Henry L. Nordhoff, former CEO and Chairman of Gen-Probe Inc., has been appointed to its Board of Directors. "We are pleased to
Read more →LCTXBioTime, Inc. Closes on $9 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)
Inc. Closes on $9 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)--June 7, 2013--BioTime, Inc. (NYSE MKT: BTX) today announced that it has closed the equity financing it announced on June 3, 2013 and received gross proceeds of $9,057,966. BioTime intends to use the net pro
Read more →LCTXBioTime, Inc. to Raise $9 Million in Registered Direct Offering
BioTime, Inc. to Raise $9 Million in Registered Direct Offering ALAMEDA, Calif., June 3, 2013 - BioTime, Inc. (NYSE MKT: BTX) today announced that it has agreed to sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in "units" with
Read more →LCTXBioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair ALAMEDA, Calif.--(BUSINESS WIRE)--May 20, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today
Read more →LCTXBioTime Appoints Franklin Berger to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)
Appoints Franklin Berger to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)--May 14, 2013--BioTime, Inc. (NYSE MKT: BTX) today announced that Franklin M. Berger, CFA, 63, has been appointed to its Board of Directors. "We are pleased to welcome a recognized biotechnology i
Read more →LCTXBioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel's Office of the Chief Scientist ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)
Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel's Office of the Chief Scientist ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--May 13, 2013--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure Neurosciences) t
Read more →LCTXBioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Announces First Quarter 2013 Financial Results and Recent Corporate ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results
Read more →LCTXBioTime Announces CFO Succession Plan Robert W. Peabody to become CFO on
Announces CFO Succession Plan Peabody to become CFO on May 10, 2013 ALAMEDA, Calif.--(BUSINESS WIRE)--April 29, 2013--BioTime, Inc. (NYSE MKT: BTX) announced today that its Senior Vice President and Chief Operating Officer, Robert W. Peabody, will reassume the additional role
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Announces Partnership with Appistry Agreement will integrate critical sources of genetic and disease information into Appistry's next-generation sequencing ("NGS") reports for c
Sciences, a Subsidiary of BioTime, Announces Partnership with Appistry will integrate critical sources of genetic and disease information into Appistry's next-generation sequencing ("NGS") reports for clinicians ALAMEDA, Calif.--(BUSINESS WIRE)--April 23, 2013--LifeMap Science
Read more →LCTXBioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke ALAMEDA, Calif.--(BUSINESS WIRE)
Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke ALAMEDA, Calif.--(BUSINESS WIRE)--April 19, 2013--BioTime, Inc. (NYSE MKT: BTX) today announced that it has entered into an exclusive license agreement with the University of Cali
Read more →LCTXLifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene - BioTime Subsidiary offers 100 select recombinant proteins in its BioReagents Portal - ALAMEDA, Calif.--(BUSINESS WIRE)
Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene Subsidiary offers 100 select recombinant proteins in its BioReagents ALAMEDA, Calif.--(BUSINESS WIRE)--April 10, 2013--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Announces Release of LifeMap Discovery TM Version 1.1 with Enhanced Therapeutic Discovery and Commercial Utility ALAMEDA, Calif.--(BUSINESS WIRE)
Sciences, a Subsidiary of BioTime, Announces Release of LifeMap Version 1.1 with Enhanced Therapeutic Discovery and Commercial Utility ALAMEDA, Calif.--(BUSINESS WIRE)--March 25, 2013--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the
Read more →LCTXBioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)--March 18, 2013--BioTime, Inc. (NYSE MKT: BTX), today reported financial results for the fourth quarter and year ended December 31, 2012 a
Read more →LCTXBioTime to Present at 25th Annual ROTH Conference ALAMEDA, Calif.--(BUSINESS WIRE)
to Present at 25th Annual ROTH Conference ALAMEDA, Calif.--(BUSINESS WIRE)--March 13, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Dr. Michael D. West, Chief Executi
Read more →LCTXBioTime Appoints Stephen C. Farrell to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)
Appoints Stephen C. Farrell to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)--March 12, 2013--BioTime, Inc. (NYSE MKT: BTX) today announced that Stephen C. Farrell has been appointed to its Board of Directors. "We are pleased to welcome an experienced executive of Steve
Read more →LCTXBioTime and Romulus Agree to Accelerate Closing Date for Second Tranche of $5 Million Financing A total of $17.6 million in new capital raised by BioTime and its subsidiaries since October 2012 ALAMEDA, Calif.--(BUSINESS
and Romulus Agree to Accelerate Closing Date for Second Tranche of $5 of $17.6 million in new capital raised by BioTime and its subsidiaries ALAMEDA, Calif.--(BUSINESS WIRE)--March 7, 2013--BioTime, Inc. (NYSE MKT: BTX) today announced it has amended its $5 million Stock and
Read more →LCTXBioTime and Subsidiary LifeMap Sciences Announce Data Mining Collaboration LifeMap Sciences' discovery platform will be used to evaluate approximately 100 million proprietary gene expression data points relating to human
and Subsidiary LifeMap Sciences Announce Data Mining Collaboration Sciences' discovery platform will be used to evaluate approximately 100 million proprietary gene expression data points relating to human embryonic stem cells generated by BioTime scientists ALAMEDA, Calif.--(
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique Visitors Annually according to Google Analytics - Company describes new product plans aimed at furthe
Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique Visitors Annually according describes new product plans aimed at further monetizing these assets - ALAMEDA, Calif.--(BUSINESS WIRE)--February 11, 2013--LifeMap Scienc
Read more →LCTXBioTime's Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-Dx TM Multi-center clinical study of a blood-based diagnostic test for the early detection o
Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM clinical study of a blood-based diagnostic test for the early detection of cancer planned for 2013 ALAMEDA, Calif.--(BUSINESS WIRE)--January 31, 2013--Bi
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored by GeneCards Scientists Report shows the existence of 80,000 human
Sciences, a Subsidiary of BioTime, Announces Publication of Research Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored by GeneCards shows the existence of 80,000 human non-redundant non-coding RNAs covering 71% of the human genome, slightly less than
Read more →LCTXBioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference ALAMEDA, Calif.--(BUSINESS WIRE)--January 18, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medic
Read more →LCTXBioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia in Europe ALAMEDA, Calif.--(BUSINESS WIRE)
Submits Protocol for Initiation of Human Clinical Trials of Renevia ALAMEDA, Calif.--(BUSINESS WIRE)--January 10, 2013--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submi
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Inc., Announces the Release of MalaCards Version 1.02 ALAMEDA, Calif.--(BUSINESS WIRE)
Sciences, a Subsidiary of BioTime, Inc., Announces the Release of MalaCards ALAMEDA, Calif.--(BUSINESS WIRE)--January 9, 2013--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of MalaCards version 1.02 on January 7. The new rel
Read more →LCTXBioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets Investor Commits to $10 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)
Signs Definitive Agreement With Geron Regarding Stem Cell Assets Commits to $10 Million Financing ALAMEDA, Calif.--(BUSINESS WIRE)--January 7, 2013--BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today
Read more →LCTXBioTime Announces the Appointment of Jeffrey Janus as Vice President Adds senior executive with significant experience in sales and marketing of research products ALAMEDA, Calif.--(BUSINESS WIRE)
Announces the Appointment of Jeffrey Janus as Vice President senior executive with significant experience in sales and marketing of ALAMEDA, Calif.--(BUSINESS WIRE)--December 20, 2012--BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice
Read more →LCTXBioTime Reports Isolation of Seven Diverse Cartilage and Bone Cell Types From Human Embryonic Stem Cells ALAMEDA, Calif.--(BUSINESS WIRE)
Reports Isolation of Seven Diverse Cartilage and Bone Cell Types From Human Embryonic Stem Cells ALAMEDA, Calif.--(BUSINESS WIRE)--December 18, 2012--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicin
Read more →LCTXBioTime CEO Dr. Michael West Presents Product Development Update at World Stem Cell Summit 2012 ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Dr. Michael West Presents Product Development Update at World Stem ALAMEDA, Calif.--(BUSINESS WIRE)--December 4, 2012--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Exec
Read more →LCTXBioTime CEO Dr. Michael West to Present at World Stem Cell Summit 2012 ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Dr. Michael West to Present at World Stem Cell Summit 2012 ALAMEDA, Calif.--(BUSINESS WIRE)--November 29, 2012--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Execu
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Inc., Launches LifeMap Discovery : A Database of Human Cellular Life for the Field of Regenerative Medicine ALAMEDA, Calif.--(BUSINESS WIRE)
Sciences, a Subsidiary of BioTime, Inc., Launches LifeMap Database of Human Cellular Life for the Field of Regenerative Medicine ALAMEDA, Calif.--(BUSINESS WIRE)--November 27, 2012--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the lau
Read more →LCTXBioTime Announces Passing of Director Abraham E. Cohen ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Passing of Director Abraham E. Cohen ALAMEDA, Calif.--(BUSINESS WIRE)--November 26, 2012--BioTime, Inc. (NYSE MKT: BTX) announced with sadness that Abraham (Barry) E. Cohen, a member of its Board of Directors, passed away on Thursday, November 22, 2012 at Mr. Cohen
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Signs Definitive Distribution Agreement with ProSpec-Tany TechnoGene ALAMEDA, Calif.--(BUSINESS WIRE)
Sciences, a Subsidiary of BioTime, Signs Definitive Distribution Agreement with ProSpec-Tany TechnoGene ALAMEDA, Calif.--(BUSINESS WIRE)--November 20, 2012--LifeMap Sciences, Inc. a subsidiary of BioTime, Inc. (NYSE MKT: BTX) announced today that it has signed a definitive di
Read more →LCTXLifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards Version 3.09 ALAMEDA, Calif.--(BUSINESS WIRE)
Sciences, a Subsidiary of BioTime, Announces Release of GeneCards ALAMEDA, Calif.--(BUSINESS WIRE)--November 19, 2012--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today the release of GeneCards , Version 3.09, on November 18, 2012. The new
Read more →LCTXBioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell ALAMEDA, Calif.--(BUSINESS WIRE)--November 15, 2012--BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into
Read more →LCTXBioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents Portal ALAMEDA, Calif.--(BUSINESS WIRE)
and Subsidiary LifeMap Sciences Announce the Launch of LifeMap ALAMEDA, Calif.--(BUSINESS WIRE)--November 14, 2012--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents (http://bioreagents.lifemapsc.com/), a new po
Read more →LCTXBioTime Announces Third Quarter 2012 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Third Quarter 2012 Financial Results and Recent Corporate ALAMEDA, Calif.--(BUSINESS WIRE)--November 9, 2012--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial res
Read more →LCTXBioTime and Subsidiary Cell Cure Neurosciences Ltd. Announce Financing ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)
and Subsidiary Cell Cure Neurosciences Ltd. Announce Financing ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--November 7, 2012--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that they have entered into a share purchase
Read more →LCTXBioTime Subsidiary OrthoCyte Corporation Announces the Appointment of Francois Binette as Vice President Adds senior executive with significant experience in developing cell-based orthopedic products ALAMEDA, Calif.--(BU
Subsidiary OrthoCyte Corporation Announces the Appointment of Francois Binette as Vice President senior executive with significant experience in developing cell-based ALAMEDA, Calif.--(BUSINESS WIRE)--November 1, 2012--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyt
Read more →LCTXBioTime's Subsidiary LifeMap Sciences, Inc. Announces the Launch of MalaCards - A Database of Human Diseases ALAMEDA, Calif.--(BUSINESS WIRE)
Subsidiary LifeMap Sciences, Inc. Announces the Launch of MalaCards A Database of Human Diseases ALAMEDA, Calif.--(BUSINESS WIRE)--October 23, 2012--BioTime, Inc. (NYSE MKT: BTX) and LifeMap Sciences, Inc. announce the launch of MalaCards, a new database of human diseases tha
Read more →LCTXLifeMap Sciences, Inc. Announces Addition to Board of Directors and Provides Update on Product Portfolio Development ALAMEDA, Calif.--(BUSINESS WIRE)
Sciences, Inc. Announces Addition to Board of Directors and Provides Update on Product Portfolio Development ALAMEDA, Calif.--(BUSINESS WIRE)--October 19, 2012--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary, LifeMap Sciences, Inc., today announced the appointment of Louis
Read more →LCTXBioTime Forms BioTime Acquisition Corporation Subsidiary will seek to acquire assets and businesses in the stem cell and regenerative medicine fields Dr. Thomas Okarma appointed Chief Executive Officer of the new company
Forms BioTime Acquisition Corporation will seek to acquire assets and businesses in the stem cell and regenerative medicine fields Thomas Okarma appointed Chief Executive Officer of the new company ALAMEDA, Calif.--(BUSINESS WIRE)--September 28, 2012--BioTime, Inc. (NYSE MKT
Read more →LCTXBioTime CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine Congress 2012 ALAMEDA, Calif.--(BUSINESS WIRE)
CEO Michael D. West to Present at Stem Cells USA & Regenerative Medicine ALAMEDA, Calif.--(BUSINESS WIRE)--September 19, 2012--BioTime, Inc. (NYSE MKT: BTX) announced that Chief Executive Officer Michael D. West, Ph.D. will present at the Stem Cells USA & Regenerative Medicine
Read more →LCTXBioTime Obtains Expanded License to HyStem Technology - BioTime now holds exclusive worldwide license for all human medical applications of the core HyStem technology - ALAMEDA, Calif.--(BUSINESS WIRE)
Obtains Expanded License to HyStem now holds exclusive worldwide license for all human medical applications ALAMEDA, Calif.--(BUSINESS WIRE)--August 27, 2012--BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expan
Read more →LCTXBioTime and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers Collagen Type X determined to be a protein specifically associated with tumor vascu
and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers Type X determined to be a protein specifically associated with tumor to detect the protein planned to be one component of PanC-DxTM, a blood-based
Read more →LCTXBioTime Announces Second Quarter 2012 Financial Results and Recent Corporate Accomplishments ALAMEDA, Calif.--(BUSINESS WIRE)
Announces Second Quarter 2012 Financial Results and Recent Corporate ALAMEDA, Calif.--(BUSINESS WIRE)--August 9, 2012--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial resu
Read more →LCTXBioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel's Office of the Chief Scientist ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)
Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel's Office of the Chief Scientist ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--August 1, 2012--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announ
Read more →LCTXBioTime Subsidiary LifeMap Sciences, Inc. Announces Financing of Up to $3 Million from Share Exchange Agreement ALAMEDA, Calif.--(BUSINESS WIRE)
Subsidiary LifeMap Sciences, Inc. Announces Financing of Up to $3 Million from Share Exchange Agreement ALAMEDA, Calif.--(BUSINESS WIRE)--July 26, 2012--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc. ("LifeMap") today announced that LifeMap entered in
Read more →LCTXBioTime Signs Agreements with Jade Therapeutics for Ophthalmological Drug Delivery Applications of HyStem Technology ALAMEDA, Calif.--(BUSINESS WIRE)
Signs Agreements with Jade Therapeutics for Ophthalmological Drug Delivery Applications of HyStem ALAMEDA, Calif.--(BUSINESS WIRE)--July 17, 2012--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine,
Read more →LCTXBioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards Version 3.08 ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)
and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards ALAMEDA, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 23, 2012--XenneX, a Division of LifeMap Sciences, Inc. and BioTime, Inc. (NYSE Amex:BTX), announced today the release of GeneCards , Version 3.08, on M
Read more →LCTXBioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc. ALAMEDA, Calif.--(BUSINESS WIRE)
Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc. ALAMEDA, Calif.--(BUSINESS WIRE)--May 21, 2012--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc. today announced that they have completed the acquisition of XenneX, Inc. through a merger of Xe
Read more →LCTXHyStem -C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease ALAMEDA, Calif.--(BUSINESS WIRE)
Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease ALAMEDA, Calif.--(BUSINESS WIRE)--May 14, 2012--BioTime, Inc. (NYSE MKT: BTX) announced today the publication of a scientific paper demonstrating the effectivene
Read more →Competitive Position
How LCTX ranks across every disease it competes inCompetitive Position is a premium feature
See how LCTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial